Kornimate/medical-research-clean huggingface dataset:
a prospective, non-randomized study to evaluate the safety and performance of the novacross™ microcatheter in femoropopliteal chronic total occlusion (cto).

Conditions: Chronic Total Occlusion

Summary: trial is to evaluate the safety and performance of the novacross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal chronic total occlusion (cto) lesion. the procedure will be conducted on a patient diagnosed with a cto in a peripheral vessel that requires revascularization.

this is an open label, single center, prospective, first in man pilot study in which the investigational device, nitiloop micro-catheter, will be tested in up to 15 patients with symptomatic peripheral arterial occlusive disease scheduled to undergo cto in an anterograde approach.

Eligibility criteria:
inclusion criteria: 1. adult aged 25-80 2. patient understands and has signed the study informed consent form. 3. patient has symptomatic peripheral artery disease (pad) requiring endovascular revascularization of a cto, evidenced by angiography, computed tomography or magnetic resonance angiography. 4. patient has an occluded femoropopliteal or infra popliteal artery 5. target femoropopliteal or infra-popliteal vessel is ≥ 2.5 mm and ≤5 mm in diameter. 6. patient has rutherford-becker classification of 2-5. exclusion criteria: 1. patient unable to give informed consent. 2. current participation in another study with any investigational drug or device. 3. patient has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated. 4. patient has a known sensitivity or allergy to anti-platelet medications. 5. patient is pregnant or lactating. 6. patient has a co-existing disease or medical condition contraindicating percutaneous intervention. 7. target lesion is in a bypass graft. 8. target lesion is in a stent (i.e., in-stent restenosis). 9. patient has had a procedure on the target limb within 7 days. 10. patient had undergone attempted treatment of the cto within the prior 3 months (to prevent a guidewire from entering dissection planes created by prior recanalization attempts. 11. vasculitis and buerger disease (thrombendarteritis obliterans) 12. evidence of embolism 13. peripheral vessel aneurysm
i̇mportance of scattered white spots detected in the duodenum and their relationship wıth zonulin

Conditions: Duodenal Diseases; White Spot Lesion

Summary: with our study, we aimed to determine whether there is a correlation between zonulin, which plays a crucial role in intestinal barrier function and is implicated in the etiopathogenesis of many chronic and autoimmune diseases, and scattered white spots lesions associated with lymphatic stasis and inflammation in the duodenum.

during esophagogastroduodenoscopy (egd), rarely encountered lesions in the duodenum present as scattered white spots (sws) on the normal mucosa. although not fully understood in terms of specific association with any particular disease and clinical significance, some studies have often observed chronic non-specific duodenitis (cnd) and intestinal lymphangiectasia (il) in lesions with sws. this condition is thought to be related to lymphatic stasis. patients included 63 individuals with identified sws during egd and 30 patients with a normal appearance of the duodenal mucosa were selected as the control group. sws lesions were categorized into two groups, grade 1 and grade 2, based on the degree of density and endoscopic appearance. biopsies were taken from the duodenum, antrum, and corpus. it was examined for il, cnd, giardiasis, and villous atrophy. venous blood samples were collected from all patients for serum zonulin levels.

Eligibility criteria:
inclusion criteria: * patients with scattered white patchy lesions in the duodenum on endoscopy and control group patients with normal duodenum on endoscopy. exclusion criteria: * active gastroenteritis * acute kidney failure * chronic kidney failure * type-1 diabetes * inflammatory bowel disease * duodenal ulcer, * duodenal tumor * autoimmune diseases
localization for deep lung nodules: microcoil versus contrast injection

Conditions: Lung Cancer

Summary: in recent years, the development of low-dose pulmonary computed tomography screening has led to the discovery of many small pulmonary nodules in the early stages. surgical resection is still the main treatment for those suspected malignant lesions. in the face of such small pulmonary nodules, accurate preoperative localization has become the key to successful resection, and the deep-seated nodules are the most challenging parts. because the deep-seated nodules cannot be localized by surface dye injection, however, it is necessary to place a fiducial marker (such as a microcoil) or contrast medium injection in combination with intraoperative fluoroscopy to ensure adequate resection of the deep-seated nodules. . this study will be carried out at the hsinchu branch of national taiwan university hospital. it is expected that 60 patients with pulmonary nodules with a depth larger than 2 cm will be randomly assigned into two groups. one group will receive microcoil placement, and the other group will receive contrast medium injection. the primary goal of the study was to compare the localization duration of the two groups of patients, the total dose of radiation exposure during localization and the incidence of location-related complications, and the secondary goals were the results of the surgical procedure, including the surgical duration.


Eligibility criteria:
inclusion criteria: deep lung lesions exclusion criteria: emphysema copd previous ilpislateral surgery

Keywords: deep-seated needle localization ct-guided thoracoscopy fiducial marker
clinical study of weifuchun treatment on precancerous lesions of gastric cancer

Conditions: Chronic Atrophic Gastritis With Hyperplasia (Diagnosis)

Summary: research purpose to elucidate the effect mechanism and clinical effective of weifuchun in the prevention and treatment of chronic atrophic gastritis and precancerous lesions of gastric cancer. from genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of weifuchun's treatment on chronic atrophic gastritis, reversing precancerous lesions of gastric cancer.

clinical research abstract title of research study：randomized clinical trial: weifuchun treatment and mechanism on precancerous lesions of gastric cancer. main responsibility person: mingyu sun research center：shuguang hospital affiliated to shanghai university of traditional chinese medicine trial objective：observe the clinical efficacy and mechanism of weifuchun in the treatment of chronic atrophic gastritis (cag) and precancerous lesions of gastric cancer (plgc) therapeutic schedule：select 60 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia from and 60 cases of chronic atrophic gastritis without intestinal metaplasia or dysplasia at the shuguang hospital affiliated to shanghai university of traditional chinese medicine. the treatment group was given weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. the control group was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal. the course of chronic atrophic gastritis with intestinal metaplasia or dysplasia group treatment is 24 weeks, the course of chronic atrophic gastritis without intestinal metaplasia or dysplasia is 12 weeks. the all patients'clinical symptoms, histopathology, gastroscopy, and physical and chemical examinations were compared between the two groups before and after treatment.

Eligibility criteria:
inclusion criteria: 1. patients with chronic atrophic gastritis and precancerous lesions according to the pathological findings under gastroscope 2. helicobacter pylori(-) exclusion criteria: 1. patients with helicobacter pylori positive infection without radical treatment. 2. patients with peptic ulcer, severe dysplasia or suspected malignant transformation. 3. pregnant or lactating women and those who are pregnant and may not have effective contraception. 4. patients with severe heart, lung, gallbladder, kidney, endocrine, hematopoietic system and neuropsychiatric diseases should not be included in this study. 5. allergic constitution or known ingredients of this medicine. 6. patients with other tumors. 7. patients participating in other clinical trials within 1 month. 8. patients with severe cirrhotic ascites and portal hypertension. 9. other diseases that interfered with the study were deemed unsuitable for the patients included in the study.

Keywords: chronic atrophic gastritis precancerous lesions of gastric cancer weifuchun randomized clinical trial mechanism
a study of guselkumab (tremfya) in chinese participants with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of chinese participants with moderate to severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * have a diagnosis of plaque psoriasis with or without psoriatic arthritis for at least 6 months before screening * a woman of childbearing potential must have a negative urine pregnancy test at screening and at baseline * agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug * agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet (uv) light sources during study * must sign an informed consent form (icf) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study exclusion criteria: * has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular) * has a history of or current signs or symptoms of liver or renal insufficiency (estimated creatinine clearance below 60 milliliter/minute \[ml/min\]); significant, progressive, or uncontrolled cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * currently has a or has a history of malignancy within 5 year before screening (exceptions are nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration and cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before screening, or malignancy, which is considered cured with minimal risk of recurrence) * history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, recurrent sinopulmonary infections, bronchiectasis, recurrent renal/urinary tract infection (example, recurrent pyelonephritis, recurrent cystitis), fungal infection (mucocutaneous candidiasis), an open, draining, or infected skin wound, or an ulcer * has previously received guselkumab
the effects of progressive core stabilization exercise training

Conditions: Core Stability; Sports Physical Therapy; Adolescent; Sports Injury; Female Athlete

Summary: a study to investigate the effects of 6 week-core stability training on adolescent volleyball players

aim: the purpose of this study is to reveal effectiveness of 6-week progressive core stabilization exercise training on muscle strength, endurance, and balance in adolescent female volleyball players. method: adolescent female volleyball players will be divided into study and control groups. both groups will continue their routine ball training (30 times/day, totally 6-week), the sg will also participate in progressive core stabilization exercise training (45 min/session, 3 times/week, totally 6-week). core muscle endurance (sit-ups test, lateral bridge test and biering sorenson test), isokinetic muscle strength test of gluteus medius (biodex 3 dynamometer in 1800/s, 2700/s, and 3600/s) and balance (star excursion balance test) will be evaluated in all players before and after 6-week follow-up.

Eligibility criteria:
inclusion criteria: * female volleyball player aged between 12-14 years * being trained by the same trainer exclusion criteria: * having had a lower or upper extremity injury lasting less than 3 months * having had a back-related operation * being diagnosed with spondylosis-spondylolisthesis * having acute low back pain * lack of family permission or * not being willingness.
use of curcumin to treat unfavorable bleeding patterns in contraceptive implant users

Conditions: Bleeding; Implants; Breakthrough Bleeding

Summary: the investigators plan to study the effects of curcumin, the active ingredient in the spice turmeric, on the irregular bleeding experienced by women who use the contraceptive implant.

the investigators are proposing a randomized, double blind placebo-controlled clinical trial over a 30-day reference period for treatment of women experiencing bothersome bleeding while using the etonogestrel (eng) contraceptive implant. the primary outcome of the study will be the total number of amenorrhea days in a 30-day reference period. the study has a number of secondary outcomes (see study objectives) focused around the efficacy of oral curcumin to stop bleeding/spotting and for how long.

Eligibility criteria:
inclusion criteria: * english speaking * women 15-45 years of age * currently using the eng implant for at least 30 days and use proven on exam (palpation of implant at screening visit) * willing to continue using the implant for at least 30 days from study enrollment * \>7 days of continuous bleeding/spotting in the last 30 days, or 2 or more episodes of bleeding/spotting in the last 30 days. * access to a reliable cell phone and must be willing to receive and respond to a daily text or email message to assess bleeding and use of study drug * negative gonorrhea/chlamydia screening performed at screening visit exclusion criteria: * postpartum within six months * post-abortion within six weeks * currently pregnant * currently breast-feeding (to be eligible, must be 4-6 weeks from cessation of breastfeeding) * undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant * bleeding dyscrasia * anticoagulation use * active cervicitis * allergy to curcumin or turmeric * history of venous thromboembolism * current or past breast or uterine malignancy * use of p450 pathway inducing drug * implant is due to be switched out in 2 months or less from enrollment * currently using oral contraceptives in addition to implant (to be eligible, needs to have a 4-6 week washout period) * prior pregnancy occurred while nexplanon/implanon was in place

Keywords: contraceptive implant irregular bleeding
preoperative music listening in odontostomatological surgery (pmlos)

Conditions: Stage I or II Micro-invasive Oral Cancer

Summary: people undergoing general anesthesia for oral cancer diagnosis and treatment often experience heightened anxiety, fear and stress with negative bodily responses, such as tachycardia, hypertension, increased myocardial consumption of o2, arrhythmias, increased peripheral resistance, hypercoagulability, immunodeficiency and catabolic response . emotional distress and pain may be managed by pre-procedurally application of anxiolytic, analgesic, and anesthetic drugs, but with potential risks or side effects such as respiratory depression, nausea and vomiting, confusion, memory loss, hypoxemia, and drug-drug interactions. this may result in adverse outcomes, such as delayed healing, increased healthcare utilization, and cost. a recent cochrane review showed that benzodiazepines reduce pre-procedural anxiety compared with placebo with a low quality of evidence. music therapy (mt), defined as the clinical and evidence-based use of music interventions by a trained professional for the purpose of achieving individualized goals within a therapeutic relationship between patient, music and music therapist 6 , may be used as a safe and cost-effective complementary intervention in adjunct to standard surgical care. during surgery, music is a powerful positive stimulus that evokes and modulates emotions as well as mood, face mask adverse stimuli, and improves emotional health through coping. music therapy and music medicine interventions are effective to prevent and treat emotional distress and pain before, during and after medical procedures . evidence from cochrane systematic reviews shows that music interventions affect positively anxiety in patients with cancer, coronary heart diseases and in patients on mechanical ventilation . some studies reported also that music interventions reduced sedative requirements in patients undergoing surgery under regional anesthesia combined with sedation, both with midazolam and propofol and also in critically ill patients in intensive care units. the primary aim of this study was to evaluate the effects of preoperative music therapy intervention compared to premedication with midazolam on anxiety, sedation and stress during general anesthesia for odontostomatological elective surgery.


Eligibility criteria:
inclusion criteria: * \>18 years * no severe neurological or psychiatric conditions, * no hearing impairment, * no drugs abuse, * american society of anesthesiologists (asa) score i to iii exclusion criteria: * \< 18 years * severe neurological or psychiatric conditions, * hearing impairment, * drugs abuse, * american society of anesthesiologists (asa) score iv to v

Keywords: music therapy stress sedation surgery anesthesia
comparison study of 3 ostomy products

Conditions: Ostomy

Summary: to purpose of the study is to evaluate and compare the efficacy of three ostomy accessory products.

the primary objective of this study was to evaluate and compare the efficacy of three ostomy accessory products in terms of leakage and wear time. secondary objectives were to evaluate and compare the safety of three ostomy accessory products, and to assess and compare the performance of the three products in terms of use and overall impression.

Eligibility criteria:
inclusion criteria: * has an ostomy * is at least 18 years of age * has a stoma for at least 3 months * other than thier ostomy is considered to have a healthy/stable health * is able to take care of their stoma exclusion criteria: * known sensitivity to any of the ostomy devices or components * is undergoing chemotherapy or radiotherapy * has participated in a clinical study within the past 30 days * has a medical condition, in which in the opinion of the investigator would not be a good candidate for the study and justifies exclusion
misoprostol for treatment of postpartum haemorrhage (pph) in home births

Conditions: Postpartum Hemorrhage (PPH)

Summary: misoprostol, a prostaglandin e1 that induces uterine contractions, has been proposed as a low cost, easy-to-use option for prevention and treatment of postpartum haemorrhage (pph), especially in settings where injectable uterotonics are not yet available or feasible to use. a double-blinded individual randomized controlled study of misoprostol versus placebo in home deliveries in four districts in the badakshan province in afghanistan. the study will recruit pregnant women who are likely to deliver at home. all women enrolled in the study will receive 600 mcg misoprostol to be self-administered as prophylaxis for pph after delivery of their baby (ies) and before delivery of the placenta. women who experience a pph will be randomized to receive either: a) standard of care + 800 mcg misoprostol (four 200 mcg tablets) or b) standard of care + four placebo tablets resembling misoprostol. in this setting, standard of care is referral.


Eligibility criteria:
inclusion criteria: * women must be pregnant * must be able to provide informed consent * must agree to have a community health worker present at the time of delivery * must agree to participate in a follow up interview by the study midwife * must agree to have pre and postpartum haemoglobin taken exclusion criteria: * women who do not meet the inclusion criteria

Keywords: postpartum hemorrhage pph misoprostol home deliveries
dietary intake after laparoscopic sleeve gastrectomy -a 5 year study

Conditions: Morbid Obesity

Summary: weight reducing surgery is the only effective therapy for morbid obese patients. sleeve gastrectomy is a popular choice for bariatric surgery because of less sequela. there is poor knowledge about the nutritional status inpatients after lsg. the aim of our study was to investigate the relationship between dietary intake and weight loss after lsg.

weight reducing surgery is the only effective therapy for morbid obese patients. restrictive type surgery is safer than mal-absorptive type surgery. laparoscopic sleeve gastrectomy is an effective surgery. in laparoscopic sleeve gastrectomy (lsg), about 90% of the stomach is surgically removed by vertical resection of the great curvature side, including the fundus. the simplicity of surgical procedures, the low occurrence of complications, and the efficiency of reducing excess weight have made lsg as a popular choice for bariatric surgery. after lsg, the amount of food eaten is drastically reduced, leading to nutritional deficiencies potentially. there is poor knowledge about the nutritional status inpatients after lsg. some literatures suggest that lsg results in less nutritional deficiencies than roux-en-y gastric bypass. the aim of our study was to investigate the relationship between dietary intake and weight loss after lsg.

Eligibility criteria:
inclusion criteria: * morbid obesity patients received laparoscopic sleeve gastrectomy for more then 5 years. bmi above 40 kg/m2 when operation. age 18-65 years old. no major psychosis or binge eating disorder. no endocrine disease. failed to lose weight with medical therapy. exclusion criteria: * current hepatitis, under steroid treatment,cancer, thyroid disease,alcoholism.

Keywords: sleeve gastrectomy, dietary intake, morbid obesity.